In summary, while preclinical studies have shown promising results, with GLP-1-RA inhibiting cancer cell proliferation and showing synergistic effects when combined with Metformin or RT, clinical data on its impact on PCa outcomes are currently insufficient. This evidence concerns the gene GCG and cancer.